PE20170667A1 - Anticuerpos anti-vasa y metodos de produccion y uso de los mismos - Google Patents
Anticuerpos anti-vasa y metodos de produccion y uso de los mismosInfo
- Publication number
- PE20170667A1 PE20170667A1 PE2017000250A PE2017000250A PE20170667A1 PE 20170667 A1 PE20170667 A1 PE 20170667A1 PE 2017000250 A PE2017000250 A PE 2017000250A PE 2017000250 A PE2017000250 A PE 2017000250A PE 20170667 A1 PE20170667 A1 PE 20170667A1
- Authority
- PE
- Peru
- Prior art keywords
- nos
- amino acid
- acid sequence
- sequence seq
- antibody
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 101000830411 Homo sapiens Probable ATP-dependent RNA helicase DDX4 Proteins 0.000 abstract 1
- 102100024770 Probable ATP-dependent RNA helicase DDX4 Human genes 0.000 abstract 1
- 238000003364 immunohistochemistry Methods 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 238000010561 standard procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/04—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; involved in cellular and subcellular movement (3.6.4)
- C12Y306/04013—RNA helicase (3.6.4.13)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Se refiere a un anticuerpo anti-VASA (mAbs) humana que comprende: a) una region variable de cadena ligera que comprende una region CDR1 con una secuencia de aminoacidos SEQ ID NOs: 83-88; CDR2 con una secuencia de aminoacidos SEQ ID NOs: 89-95 y CDR3 con una secuencia de aminoacidos SEQ ID NOs: 96-104 y b) una region variable de cadena pesada que comprende una region CDR1 con una secuencia de aminoacidos SEQ ID NOs: 105-112; CDR2 con una secuencia de aminoacidos SEQ ID NOs: 113-121 y CDR3 con una secuencia de aminoacidos SEQ ID NOs: 122-131. Tambien se refiere a una molecula de acido nucleico que codifica la cadena pesada y ligera del anticuerpo. Dicho anticuerpo es util en metodos estandar de purificacion por inmunoafinidad, inmunohistoquimica e inmunoterapia
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051130P | 2014-09-16 | 2014-09-16 | |
| US201462089054P | 2014-12-08 | 2014-12-08 | |
| PCT/US2015/050449 WO2016044436A2 (en) | 2014-09-16 | 2015-09-16 | Anti-vasa antibodies, and methods of production and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170667A1 true PE20170667A1 (es) | 2017-06-06 |
Family
ID=55454121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017000250A PE20170667A1 (es) | 2014-09-16 | 2015-09-16 | Anticuerpos anti-vasa y metodos de produccion y uso de los mismos |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US9403913B2 (es) |
| EP (1) | EP3194448A4 (es) |
| JP (2) | JP2017532953A (es) |
| KR (1) | KR20170056521A (es) |
| CN (1) | CN106573985A (es) |
| AP (1) | AP2017009758A0 (es) |
| AU (1) | AU2015317813B2 (es) |
| BR (1) | BR112017003263A2 (es) |
| CA (1) | CA2959179A1 (es) |
| CL (1) | CL2017000402A1 (es) |
| CO (1) | CO2017001724A2 (es) |
| CR (1) | CR20170067A (es) |
| DO (1) | DOP2017000050A (es) |
| EA (1) | EA201790236A1 (es) |
| EC (1) | ECSP17011262A (es) |
| GT (1) | GT201700036A (es) |
| IL (1) | IL250451A0 (es) |
| MX (1) | MX358243B (es) |
| NI (1) | NI201700022A (es) |
| PE (1) | PE20170667A1 (es) |
| PH (1) | PH12017500309A1 (es) |
| SG (1) | SG11201701016WA (es) |
| SV (1) | SV2017005393A (es) |
| TN (1) | TN2017000066A1 (es) |
| TW (1) | TW201619194A (es) |
| WO (1) | WO2016044436A2 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ571300A (en) | 2006-04-07 | 2011-12-22 | Warner Chilcott Co Llc | Antibodies that bind human protein tyrosine phosphatase beta (HPTPBeta) and uses thereof |
| CA2850830A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
| PE20170667A1 (es) * | 2014-09-16 | 2017-06-06 | Ovascience Inc | Anticuerpos anti-vasa y metodos de produccion y uso de los mismos |
| SG11201900464TA (en) | 2016-07-20 | 2019-02-27 | Aerpio Therapeutics Inc | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| CN120058958A (zh) | 2018-09-24 | 2025-05-30 | 视点制药公司 | 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体 |
| WO2020102565A2 (en) | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Systems and methods for nondestructive testing of gametes |
| WO2021096829A1 (en) * | 2019-11-11 | 2021-05-20 | Vanderbilt University | Human monoclonal antibodies to hantavirus and methods of use therefor |
| CN120405134A (zh) * | 2024-01-30 | 2025-08-01 | 抟相医药(杭州)有限公司 | 基于凝聚体荧光漂白恢复技术(Drop-FRAP)的生物大分子相互作用调节剂筛选平台 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996039518A1 (en) * | 1995-06-05 | 1996-12-12 | Bionebraska, Inc. | Lead binding polypeptides and nucleotides coding therefor |
| EP1233978A4 (en) * | 1999-11-18 | 2003-07-23 | Brigham & Womens Hospital | COMPOSITIONS AND METHODS FOR IMPROVED DIAGNOSIS AND TREATMENT OF GERM CELL TUMORS |
| US6875854B1 (en) * | 1999-11-18 | 2005-04-05 | The Brigham And Women's Hospital, Inc. | Compositions and methods for the improved diagnosis and treatment of germ cell tumors |
| US7955846B2 (en) | 2004-05-17 | 2011-06-07 | The General Hospital Corporation | Compositions comprising female germline stem cells and methods of use thereof |
| US20060010509A1 (en) | 2004-05-17 | 2006-01-12 | Joshua Johnson | Methods and compositions for producing germ cells from bone marrow derived germline stem cells |
| PT1674111E (pt) * | 2004-07-09 | 2010-12-15 | Chugai Pharmaceutical Co Ltd | Anticorpo anti-glipicano 3 |
| EP2208783A1 (en) * | 2004-12-22 | 2010-07-21 | Chugai Seiyaku Kabushiki Kaisha | Method of producing an antibody using a cell in which the function of fucose transporter is inhibited |
| MX2011003142A (es) | 2008-09-25 | 2011-05-19 | Univ Tokyo Nat Univ Corp | Anticuerpo anti-vasa de atun. |
| CN102395603A (zh) * | 2008-12-26 | 2012-03-28 | 国立大学法人东京大学 | 使用抗lgr7抗体的癌症的诊断和治疗 |
| JP5769316B2 (ja) * | 2009-08-06 | 2015-08-26 | イムナス・ファーマ株式会社 | Ａβオリゴマーに特異的に結合する抗体およびその利用 |
| EA201391523A1 (ru) | 2011-04-14 | 2014-03-31 | Зе Дженерэл Хоспитэл Корпорейшн | Композиции и способы для переноса энергии митохондрий аутологичных герминативных клеток |
| EP2726601B1 (en) * | 2011-06-29 | 2018-12-26 | The General Hospital Corporation | Compositions and methods for enhancing bioenergetic status in female germ cells |
| JP2016503817A (ja) * | 2012-12-31 | 2016-02-08 | ディヴェロップメント センター フォー バイオテクノロジー | アンチグラニュリシン抗体及びその使用方法 |
| PE20170667A1 (es) * | 2014-09-16 | 2017-06-06 | Ovascience Inc | Anticuerpos anti-vasa y metodos de produccion y uso de los mismos |
| US20180002662A1 (en) * | 2015-01-13 | 2018-01-04 | President And Fellows Of Harvard College | Purification of germ stem cells by targeting mrp9 |
-
2015
- 2015-09-16 PE PE2017000250A patent/PE20170667A1/es not_active Application Discontinuation
- 2015-09-16 TW TW104130554A patent/TW201619194A/zh unknown
- 2015-09-16 KR KR1020177005227A patent/KR20170056521A/ko not_active Withdrawn
- 2015-09-16 CA CA2959179A patent/CA2959179A1/en not_active Abandoned
- 2015-09-16 US US14/856,380 patent/US9403913B2/en not_active Expired - Fee Related
- 2015-09-16 MX MX2017002390A patent/MX358243B/es active IP Right Grant
- 2015-09-16 WO PCT/US2015/050449 patent/WO2016044436A2/en not_active Ceased
- 2015-09-16 EA EA201790236A patent/EA201790236A1/ru unknown
- 2015-09-16 EP EP15841982.0A patent/EP3194448A4/en not_active Withdrawn
- 2015-09-16 SG SG11201701016WA patent/SG11201701016WA/en unknown
- 2015-09-16 JP JP2017511337A patent/JP2017532953A/ja active Pending
- 2015-09-16 CN CN201580045293.8A patent/CN106573985A/zh active Pending
- 2015-09-16 BR BR112017003263A patent/BR112017003263A2/pt not_active Application Discontinuation
- 2015-09-16 CR CR20170067A patent/CR20170067A/es unknown
- 2015-09-16 AP AP2017009758A patent/AP2017009758A0/en unknown
- 2015-09-16 AU AU2015317813A patent/AU2015317813B2/en not_active Ceased
- 2015-09-16 TN TN2017000066A patent/TN2017000066A1/en unknown
-
2016
- 2016-07-06 US US15/203,040 patent/US9567404B2/en not_active Expired - Fee Related
- 2016-12-30 US US15/395,114 patent/US20170107299A1/en not_active Abandoned
-
2017
- 2017-02-05 IL IL250451A patent/IL250451A0/en unknown
- 2017-02-17 CL CL2017000402A patent/CL2017000402A1/es unknown
- 2017-02-20 PH PH12017500309A patent/PH12017500309A1/en unknown
- 2017-02-21 EC ECIEPI201711262A patent/ECSP17011262A/es unknown
- 2017-02-23 CO CONC2017/0001724A patent/CO2017001724A2/es unknown
- 2017-02-23 GT GT201700036A patent/GT201700036A/es unknown
- 2017-02-23 NI NI201700022A patent/NI201700022A/es unknown
- 2017-02-23 SV SV2017005393A patent/SV2017005393A/es unknown
- 2017-02-23 DO DO2017000050A patent/DOP2017000050A/es unknown
- 2017-09-25 US US15/714,823 patent/US20180155445A1/en not_active Abandoned
-
2018
- 2018-05-24 JP JP2018099529A patent/JP2018148915A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170667A1 (es) | Anticuerpos anti-vasa y metodos de produccion y uso de los mismos | |
| PE20170289A1 (es) | Anticuerpos anti tigit | |
| PE20151289A1 (es) | Anticuerpos que se unen al tl1a y sus usos | |
| PE20170288A1 (es) | Anticuerpos anti-lag3 y fragmentos de union a antigeno | |
| MX2022011659A (es) | Proteinas de union a antigeno que se unen a pd-l1. | |
| MX2018006925A (es) | Anticuerpos monoclonales anti-ctla4 humano quimericos y humanizados y sus usos. | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| PE20180950A1 (es) | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador | |
| NZ728749A (en) | Anti-pd-l1 antibodies | |
| PE20160553A1 (es) | Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7 | |
| MX388181B (es) | Anticuerpos anti-pd-1. | |
| EA201792589A1 (ru) | Антитела против cd123 и конъюгаты указанных антител | |
| PE20180042A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| PE20150002A1 (es) | Anticuerpos anti-fcrn | |
| PE20161392A1 (es) | Combinacion de lenalidomida y constructo de polipeptido, y sus usos | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| CL2017000912A1 (es) | Anticuerpos que se unen a ccr6 y sus usos | |
| EA201600276A1 (ru) | Анти-il-17-антитела, способ их получения и способ применения | |
| EA201591974A1 (ru) | Антитела человека, связывающиеся с g-белком rsv | |
| EA201990672A1 (ru) | Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты | |
| PE20171107A1 (es) | Anticuerpos mejorados contra il-6 | |
| NZ750244A (en) | Humanized antibodies transmigrating the blood-brain barrier and uses thereof | |
| CU24556B1 (es) | Anticuerpos anti-basigin humanizados | |
| MX2017001642A (es) | ANTICUERPO IGß ANTIHUMANO NOVEDOSO. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |